Provided is a method of using an aptamer for detecting a glycated hemoglobin in a whole blood, the method includes that the aptamer is provided, the aptamer includes a DNA sequence selected from the group consisting of derived sequences of SEQ ID NOs: 1, 2, 3, and 4, in which the derived sequences refer to that 3′ end and/or 5′ end of the derived sequences are modified, and the derived sequences have 90% identity to the SEQ ID NOs: 1, 2, 3, and 4. The aptamer and the whole blood are contacted. A concentration of a conjugate of the aptamer and the glycated hemoglobin is estimated. Provided also is a nanoelectronic aptasensor including the above aptamer.

The invention relates to the field of personalized medicine, and the ability to administer targeted therapies consequently to biomarkers functional identification. In particular, the invention relates to the field of clinical applicable methods for the characterization, and especially the functional evaluation, of genetic variants in a patient. In particular, the invention relates to the field of the characterization, and classification, of variants of uncertain significance (VUS) or other unreported variants in patients. The in vitro method presented here is effective for the characterization of the functional impact of genetic variants in a patient, in particular of VUS, such as BRCA1 and BRCA2 VUS. The inventors have shown that this experimental framework can be used to obtain the necessary biological evidence of VUS function required for the prescription of targeted treatment within three weeks, which is compatible with use in clinical application.

The present invention discloses a sequencing library comprising a nucleotide sequence. The sequence comprises a linker sequence and two target sequences. Two ends of the linker sequence are respectively linked to the target sequences and the two target sequences are direct repeat sequences. The present invention further discloses preparation and use of the sequencing library. The present invention overcomes the high error rate problem of current DNA sequencing technologies, especially in a way of very low coverage bias, and can be used to detect low frequency mutations in different kinds of samples.

The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula I, wherein Formula I in the 5′-to-3′ direction comprises: A-(B-L).sub.J-C-M-T-D; wherein A is 0-15 nucleotides in length; B is 4-12 nucleotides in length; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L).sub.J-C and T-D are separate nucleic acid strands; T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.

Methods and compositions for digital profiling of nucleic acid sequences present in a sample are provided.

The subject matter disclosed herein is generally directed to methods and compositions for tagging cells of interest, tracking evolution of the tagged cells, and recovering the original tagged cells for further study. Specifically, cells are tagged with a DNA construct encoding a barcode sequence comprising a guide sequence. Barcoded cells can then be recovered using a reporter construct having CRISPR target sequences specific for the cell having a barcode of interest.

Molecular beacons and developmental methods related thereto. Methods include obtaining a nucleotide sequence for an aptamer that binds to a target analyte. The aptamer comprises a binding domain nucleotide sequence, a first domain nucleotide sequence, and a displacement domain nucleotide sequence complementary to the first domain nucleotide sequence. A molecular beacon is developed based on the nucleotide sequence of the aptamer by preserving the binding domain nucleotide sequence and truncating or extending one or both of the first domain nucleotide sequence or the displacement domain nucleotide sequence. The resultant molecular beacon is developed such that the molecular beacon comprises a Gibbs free energy value that is greater than the Gibbs free energy value of the aptamer.

Method and apparatus for obtaining range information associated with a target using light detection and ranging (LiDAR). An emitter transmits a set of pulses of electromagnetic radiation to illuminate a target. The set of pulses includes a pair of emitted pulses with different waveform characteristics, such as slightly different phases. A detector receives a reflected set of pulses from the target. The received set of pulses includes a pair of received pulses with corresponding different waveform characteristics. The detector determines the range information by decoding the received pulses, such as by calculating an average of the phase differential in the received pulses. In this way, a single stage detector can be used without the need for separate I/Q (in-phase and quadrature) channels. Phase chirping can be used so that each successive pair of pulses has a different phase difference. Other waveform characteristics can be used including frequency, amplitude, shape, etc.

The present invention includes compositions and methods comprising viral vector systems for multiplexed activation of endogenous genes as immunotherapy and viral-based immune-gene therapy.

Provided are RNA polynucleotide sequences referred to as “EXO-Codes.” The RNA polynucleotides comprise one or more nucleotide sequences that facilitate preferential enrichment of secreted membranous vesicles that contain the EXO-Codes. Nucleotide motifs that contribute to these properties of the EXO-Codes are described. Modified eukaryotic cells comprising EXO-Codes are provided, and include lymphocytes such as T cells. EXO-Codes may comprise a cargo that provides a prophylactic or therapeutic effect. Exosome preparations comprising the EXO-codes are provided. Pharmaceutical compositions comprising EXO-Codes, expression vectors encoding them, and methods of using the pharmaceutical formulations are provided. The pharmaceutical compositions may comprise the EXO-Codes within membranous structures, such as exosomes. Cells that express or otherwise include the EXO-Codes are included, as are method for separating membranous structures that contain the EXO-codes from the cells.